Aripiprazole

Irritability, Schizophrenia, Agitation + 10 more

Treatment

1 FDA approval

20 Active Studies for Aripiprazole

What is Aripiprazole

Aripiprazole

The Generic name of this drug

Treatment Summary

Aripiprazole lauroxil is an antipsychotic medication used to treat schizophrenia in adults. It works by blocking certain receptors in the brain that are responsible for symptoms like delusions, hallucinations, thought disorders, and social withdrawal. Aripiprazole lauroxil was approved by the FDA in 2015 under the brand name Aristada and can be administered as an intramuscular injection. In July 2020, a new formulation called Aristada Initio was approved which allows for a faster response time of the drug when combined with a single 30 mg oral dose. Aripiprazole lauroxil is generally effective

Abilify

is the brand name

image of different drug pills on a surface

Aripiprazole Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Abilify

Aripiprazole

2002

454

Approved as Treatment by the FDA

Aripiprazole, also known as Abilify, is approved by the FDA for 1 uses such as Schizophrenia .

Schizophrenia

Used to treat Schizophrenia in combination with Aripiprazole lauroxil

Effectiveness

How Aripiprazole Affects Patients

Aripiprazole is a medication used to reduce symptoms of schizophrenia, such as delusions or hallucinations. It works by modifying the activity of certain chemicals in the brain. Taking aripiprazole lauroxil is not known to affect one's sexual function or levels of prolactin, a hormone produced in the body.

How Aripiprazole works in the body

Aripiprazole works by targeting different receptors in the brain. It acts like a partial stimulator (agonist) at dopamine D2 and serotonin 5-HT1A receptors, and an inhibitor (antagonist) at serotonin 5-HT2A receptors. This combination leads to reduced positive symptoms of schizophrenia, like hallucinations and delusions, while also improving negative symptoms, like lack of motivation and impaired thinking. Aripiprazole also blocks alpha-1 adrenergic receptors, leading to orthostatic hypotension, and histamine H1 receptors, which can cause drowsiness. The drug binds to up to 90% of dopamine

When to interrupt dosage

The suggested measure of Aripiprazole is contingent upon the determined circumstances. The quantity of dosage is subject to the technique of delivery, as delineated in the table below.

Condition

Dosage

Administration

Schizophrenia

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 15.0 mg, 2.0 mg, 300.0 mg, 400.0 mg, 1.0 mg/mL, 9.75 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 7.5 mg/mL

Tablet - Oral, Tablet, , Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Solution, Solution - Oral, Injection, solution - Intramuscular, Injection, solution, Injection, powder, lyophilized, for suspension, extended release - Intramuscular, Injection, powder, lyophilized, for suspension, extended release, Injection, Injection - Intramuscular

Irritability

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 15.0 mg, 2.0 mg, 300.0 mg, 400.0 mg, 1.0 mg/mL, 9.75 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 7.5 mg/mL

Tablet - Oral, Tablet, , Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Solution, Solution - Oral, Injection, solution - Intramuscular, Injection, solution, Injection, powder, lyophilized, for suspension, extended release - Intramuscular, Injection, powder, lyophilized, for suspension, extended release, Injection, Injection - Intramuscular

Bipolar Disorder

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 15.0 mg, 2.0 mg, 300.0 mg, 400.0 mg, 1.0 mg/mL, 9.75 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 7.5 mg/mL

Tablet - Oral, Tablet, , Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Solution, Solution - Oral, Injection, solution - Intramuscular, Injection, solution, Injection, powder, lyophilized, for suspension, extended release - Intramuscular, Injection, powder, lyophilized, for suspension, extended release, Injection, Injection - Intramuscular

Acute Coryza

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 15.0 mg, 2.0 mg, 300.0 mg, 400.0 mg, 1.0 mg/mL, 9.75 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 7.5 mg/mL

Tablet - Oral, Tablet, , Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Solution, Solution - Oral, Injection, solution - Intramuscular, Injection, solution, Injection, powder, lyophilized, for suspension, extended release - Intramuscular, Injection, powder, lyophilized, for suspension, extended release, Injection, Injection - Intramuscular

Alzheimer's Disease

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 15.0 mg, 2.0 mg, 300.0 mg, 400.0 mg, 1.0 mg/mL, 9.75 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 7.5 mg/mL

Tablet - Oral, Tablet, , Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Solution, Solution - Oral, Injection, solution - Intramuscular, Injection, solution, Injection, powder, lyophilized, for suspension, extended release - Intramuscular, Injection, powder, lyophilized, for suspension, extended release, Injection, Injection - Intramuscular

Psychotic Depression

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 15.0 mg, 2.0 mg, 300.0 mg, 400.0 mg, 1.0 mg/mL, 9.75 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 7.5 mg/mL

Tablet - Oral, Tablet, , Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Solution, Solution - Oral, Injection, solution - Intramuscular, Injection, solution, Injection, powder, lyophilized, for suspension, extended release - Intramuscular, Injection, powder, lyophilized, for suspension, extended release, Injection, Injection - Intramuscular

Schizophrenia

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 15.0 mg, 2.0 mg, 300.0 mg, 400.0 mg, 1.0 mg/mL, 9.75 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 7.5 mg/mL

Tablet - Oral, Tablet, , Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Solution, Solution - Oral, Injection, solution - Intramuscular, Injection, solution, Injection, powder, lyophilized, for suspension, extended release - Intramuscular, Injection, powder, lyophilized, for suspension, extended release, Injection, Injection - Intramuscular

Agitation

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 15.0 mg, 2.0 mg, 300.0 mg, 400.0 mg, 1.0 mg/mL, 9.75 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 7.5 mg/mL

Tablet - Oral, Tablet, , Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Solution, Solution - Oral, Injection, solution - Intramuscular, Injection, solution, Injection, powder, lyophilized, for suspension, extended release - Intramuscular, Injection, powder, lyophilized, for suspension, extended release, Injection, Injection - Intramuscular

Autism Spectrum Disorder (ASD)

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 15.0 mg, 2.0 mg, 300.0 mg, 400.0 mg, 1.0 mg/mL, 9.75 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 7.5 mg/mL

Tablet - Oral, Tablet, , Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Solution, Solution - Oral, Injection, solution - Intramuscular, Injection, solution, Injection, powder, lyophilized, for suspension, extended release - Intramuscular, Injection, powder, lyophilized, for suspension, extended release, Injection, Injection - Intramuscular

Tourette Syndrome

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 15.0 mg, 2.0 mg, 300.0 mg, 400.0 mg, 1.0 mg/mL, 9.75 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 7.5 mg/mL

Tablet - Oral, Tablet, , Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Solution, Solution - Oral, Injection, solution - Intramuscular, Injection, solution, Injection, powder, lyophilized, for suspension, extended release - Intramuscular, Injection, powder, lyophilized, for suspension, extended release, Injection, Injection - Intramuscular

Bipolar Disorder

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 15.0 mg, 2.0 mg, 300.0 mg, 400.0 mg, 1.0 mg/mL, 9.75 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 7.5 mg/mL

Tablet - Oral, Tablet, , Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Solution, Solution - Oral, Injection, solution - Intramuscular, Injection, solution, Injection, powder, lyophilized, for suspension, extended release - Intramuscular, Injection, powder, lyophilized, for suspension, extended release, Injection, Injection - Intramuscular

Bipolar Disorder

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 15.0 mg, 2.0 mg, 300.0 mg, 400.0 mg, 1.0 mg/mL, 9.75 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 7.5 mg/mL

Tablet - Oral, Tablet, , Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Solution, Solution - Oral, Injection, solution - Intramuscular, Injection, solution, Injection, powder, lyophilized, for suspension, extended release - Intramuscular, Injection, powder, lyophilized, for suspension, extended release, Injection, Injection - Intramuscular

Depression

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 15.0 mg, 2.0 mg, 300.0 mg, 400.0 mg, 1.0 mg/mL, 9.75 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 7.5 mg/mL

Tablet - Oral, Tablet, , Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Solution, Solution - Oral, Injection, solution - Intramuscular, Injection, solution, Injection, powder, lyophilized, for suspension, extended release - Intramuscular, Injection, powder, lyophilized, for suspension, extended release, Injection, Injection - Intramuscular

Warnings

Aripiprazole Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Aripiprazole may interact with Pulse Frequency

There are 20 known major drug interactions with Aripiprazole.

Common Aripiprazole Drug Interactions

Drug Name

Risk Level

Description

Acepromazine

Major

Aripiprazole may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.

Aclidinium

Major

The risk or severity of adverse effects can be increased when Aripiprazole is combined with Aclidinium.

Alfuzosin

Major

Aripiprazole may increase the hypotensive activities of Alfuzosin.

Amisulpride

Major

Aripiprazole may increase the antipsychotic activities of Amisulpride.

Aripiprazole lauroxil

Major

Aripiprazole may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole lauroxil.

Aripiprazole Toxicity & Overdose Risk

In rats, an intramuscular injection of aripiprazole is found to be non-toxic up to 60mg. However, in females, males, and monkeys, the oral LD50 is found to be 705mg/kg, 965mg/kg and greater than 2000mg/kg, respectively. Common side effects of overdosing include vomiting, drowsiness, tremor, and akathisia. In some cases, more serious symptoms such as confusion, seizures, irregular heartbeat, and breathing problems may be seen. Aripiprazole can also cause Neuroleptic Malignant Syndrome (N

image of a doctor in a lab doing drug, clinical research

Aripiprazole Novel Uses: Which Conditions Have a Clinical Trial Featuring Aripiprazole?

170 active clinical trials are examining the utility of Aripiprazole in managing Schizophrenia and other related conditions.

Condition

Clinical Trials

Trial Phases

Schizophrenia

97 Actively Recruiting

Phase 3, Not Applicable, Early Phase 1, Phase 4, Phase 1, Phase 2

Bipolar Disorder

0 Actively Recruiting

Bipolar Disorder

0 Actively Recruiting

Acute Coryza

1 Actively Recruiting

Not Applicable

Alzheimer's Disease

15 Actively Recruiting

Not Applicable, Phase 2, Phase 1

Psychotic Depression

0 Actively Recruiting

Irritability

8 Actively Recruiting

Phase 2, Not Applicable, Early Phase 1, Phase 4

Schizophrenia

31 Actively Recruiting

Early Phase 1, Not Applicable, Phase 4

Agitation

3 Actively Recruiting

Phase 2, Phase 3, Not Applicable

Bipolar Disorder

0 Actively Recruiting

Autism Spectrum Disorder (ASD)

60 Actively Recruiting

Phase 2, Phase 3, Not Applicable, Phase 1, Phase 4, Early Phase 1

Depression

213 Actively Recruiting

Phase 3, Phase 2, Not Applicable, Phase 4, Phase 1, Early Phase 1

Tourette Syndrome

3 Actively Recruiting

Not Applicable

Aripiprazole Reviews: What are patients saying about Aripiprazole?

5

Patient Review

1/19/2015

Aripiprazole for Additional Medications to Treat Depression

I had been searching for two decades to find a way to combat my depression. I'd tried various types of antidepressants with little-to-no success before finally finding relief in a combination of bupropion, escitalopram, and other mood medications. Once we added Abilify to the mix, it was like a weight had been lifted off my shoulders. I'm able to function now where I wasn't before, and I couldn't be happier with the results.

5

Patient Review

3/9/2015

Aripiprazole for Additional Medications to Treat Depression

Lexapro and lithium were good, but adding abilify really helped fine-tune my medication regimen.

5

Patient Review

3/8/2021

Aripiprazole for Additional Medications to Treat Depression

This medication has been a game-changer for me in terms of my depression. I feel so much more clearheaded and energetic without feeling manic.

4.7

Patient Review

2/14/2013

Aripiprazole for Bipolar Disorder in Remission

4

Patient Review

8/15/2022

Aripiprazole for Additional Medications to Treat Depression

I was really hoping this would help me with the anxiety attacks I've been having. So far, it's made them more bearable and given me back some energy. fingers crossed it keeps working!

3.3

Patient Review

9/28/2021

Aripiprazole for Schizophrenia

I've been taking this medication for over 10 years now. When I first started, it was great! It helped with my anxiety and nightmares. But then, after a while, I started to experience some negative side effects like gambling and increased sexual desire. And now I find that I'm sleeping more than 16 hours a day and have zero motivation.

3.3

Patient Review

10/24/2017

Aripiprazole for Bipolar Disorder in Remission

Overall this medication does what it's supposed to, but I've gained a lot of weight since starting it which is really frustrating.

3

Patient Review

4/16/2021

Aripiprazole for Additional Medications to Treat Depression

I've only just started this treatment in place of Prozac, which I was taking for years. I'm also continuing to take cymbalta. I'm feeling a bit nervous about the change, so reviews are helpful. I hope that this will work for my depression and suicidal thoughts.

2.3

Patient Review

10/16/2015

Aripiprazole for Bipolar I Disorder with Most Recent Episode Mixed

Unfortunately, this medication caused me to have manic episodes which resulted in uncontrolled spending. I was also only sleeping 3-4 hours a night, which made the effects even worse.

2.3

Patient Review

7/31/2017

Aripiprazole for Additional Medications to Treat Depression

I experienced tremors and extreme dizziness after taking just 5mg of this medication. I absolutely need to find a replacement soon.

2

Patient Review

10/5/2015

Aripiprazole for Additional Medications to Treat Depression

I tried to quit taking Abilify and it gave me Tardive Dyskinesia. It's really painful, my jaw is constantly aching and my mouth is moving involuntarily from side to side. I want to get off of the drug because I've gained 50 pounds, but it's proving difficult.

2

Patient Review

7/23/2021

Aripiprazole for Additional Medications to Treat Depression

I experienced unexpected drowsiness after taking this medication for a few weeks. One day, I was driving and became so exhausted that I could barely keep my eyes open. As a result, I got into a car accident. Because of this incident (and others like it), I no longer take this medication.

1.7

Patient Review

6/20/2014

Aripiprazole for Additional Medications to Treat Depression

This medication was a huge disappointment and actually made things worse. I wouldn't wish it on my worst enemy.

1

Patient Review

3/7/2021

Aripiprazole for Additional Medications to Treat Depression

I've used this for years without any improvement. It's not a good product.

1

Patient Review

3/7/2021

Aripiprazole for Schizophrenia

I've used this for years without any good results.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about aripiprazole

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does aripiprazole make you high?

"Dopamine agonists drugs such as aripiprazole work by activating dopamine receptors in the brain, which has the effect of opening up those pathways. Some of the potential side effects of this include euphoria, increased orgasmic activity, and developing addictions to activities such as gambling, shopping, binge eating, and sex."

Answered by AI

What is aripiprazole is used for?

"Aripiprazole is a medication used to treat mental conditions such as bipolar disorder, depression, and schizophrenia. It can also be used in children to treat irritability associated with autistic disorder and Tourette syndrome."

Answered by AI

What side effects does aripiprazole have?

"You may experience a headache, nervousness, or restlessness. You may also feel dizzy, unsteady, or have trouble keeping your balance. Additionally, you may have heartburn, constipation, diarrhea, or stomach pain."

Answered by AI

Is aripiprazole the same as Xanax?

"The pill form of Aripiprazole is a prescription drug that comes in four oral dosage forms. Alprazolam is a prescription medication that is available as brand name drugs called Alprazolam Intensol, Xanax, or Xanax XR."

Answered by AI

Clinical Trials for Aripiprazole

Image of Training is all online and is available to participate in the study from anywhere in the US, run from a site in PA in Wexford, United States.

Emotional Intelligence Training for Autism

18+
All Sexes
Wexford, PA

Subjects are enrolled in pairs. Pairs consist of an autistic adult age 18-36 and a non-autistic learning partner who has a relationship with the autistic adult, such as a parent. The autistic adult in each pair receives the first stage of Kairon's online leadership training consisting of emotional literacy and healthy relationship topics. The learning partner in each pair receives Kairon's autism accommodation training while encouraging and providing feedback to their paired autistic adult. After training, both people in each pair evaluate the trainings' impacts on themselves and on their partner. Specifically, each autistic adult evaluates both the effectiveness of the leadership training they received and the effectiveness of the autism accommodation training that their paired learning partner received. Each learning partner evaluates both the effectiveness of the autism accommodation training they received and the effectiveness of the leadership training that their paired autistic adult received.

Recruiting
Has No Placebo

Training is all online and is available to participate in the study from anywhere in the US, run from a site in PA

Kairon Connect, PBC

Have you considered Aripiprazole clinical trials?

We made a collection of clinical trials featuring Aripiprazole, we think they might fit your search criteria.
Go to Trials
Image of UCLA Semel Institute in Los Angeles, United States.

Psilocybin-assisted CBT for Depression

21 - 60
All Sexes
Los Angeles, CA

The primary objectives of this clinical investigation are to (1) determine the acceptability and feasibility of joining psilocybin-assisted therapy with cognitive-behavioral therapy (PA-CBT) for patients with depression, (2) optimize CBT to most effectively integrate the psilocybin experience with psychotherapy and (3) examine the clinical benefit of psilocybin as an adjunct to cognitive-behavioral therapy (CBT) for major depressive disorder. This study is a randomized, two-arm, fixed dose trial that will test the feasibility, acceptability, and participant and therapist adherence to PA-CBT. Both treatment arms will receive two doses of psilocybin (10mg and then 25mg, separated by one month). In Phase II, participants will be randomized (1:1) to either a 12-session PA-CBT or a 6-session standard psilocybin-assisted therapy (PAT) condition (3 hours of preparation plus 3 hours of supportive therapy integration following the psilocybin experiences).

Phase 1 & 2
Recruiting

UCLA Semel Institute

Have you considered Aripiprazole clinical trials?

We made a collection of clinical trials featuring Aripiprazole, we think they might fit your search criteria.
Go to Trials
Image of University of Rochester Medical Center in Rochester, United States.

Deaf CBT-TS for Suicide Risk

18+
All Sexes
Rochester, NY

The goal of this clinical trial is to learn if a short, Zoom-based intervention, Cognitive Behavioral Therapy for Treatment-Seeking for Deaf Individuals (Deaf CBT-TS) can change beliefs about mental health treatment and increase treatment-seeking behaviors in Deaf adults with untreated mental health or alcohol use problems. It will also see if Deaf CBT-TS may reduce suicide risk and explore factors that may increase the effectiveness of Deaf CBT-TS. The main questions it aims to answer are: * Does Deaf CBT-TS increase positive beliefs about treatment and increase treatment-seeking behaviors? * Does Deaf CBT-TS increase hope and reduce mental health symptoms, suicide ideation, and alcohol use? * Is Deaf CBT-TS more effective for individuals with less cultural stress compared to those with high levels of cultural stress? * Is Deaf CBT-TS more effective for Deaf individuals in residential areas with more Deaf resources than those with less Deaf resources? Researchers will compare individuals who complete Deaf CBT-TS to those on a waitlist to see if Deaf CBT-TS works to increase positive beliefs about treatment and treatment-seeking behaviors. Participants will: * Complete a baseline assessment including demographic information, measures of hope, general mental health and functioning, alcohol use, suicide ideation, cultural stress, and beliefs about treatment. * Receive Deaf CBT-TS (2 sessions) or be placed on a waitlist with the option of receiving Deaf CBT-Ts after 4 months * Complete two follow-up assessments in 2 and 4 months.

Waitlist Available
Has No Placebo

University of Rochester Medical Center

Image of Sunwise Clinical Research /ID# 277555 in Walnut Creek, United States.

Icalcaprant for Depression

18 - 65
All Sexes
Walnut Creek, CA

Major depressive disorder (MDD; depression) is a mood disorder that causes a continued feeling of sadness and loss of interest. It is a common and serious illness that can cause both emotional and physical symptoms such as feelings of sadness, irritability, not being able to focus on activities, tiredness, changes in eating habits, and aches and pains. This study will assess the changes in disease activity and adverse events of oral Icalcaprant in adult participants with major depressive disorder who are currently experiencing a major depressive episode (MDE). Icalcaprant is an investigational drug being developed for the treatment of depressive episodes in adult participants with major depressive disorder. Participants are placed in 1 of 3 groups, called treatment arms. There is a 1 in 3 chance that a participant will be assigned to placebo treatment. Around 195 adult participant with major depressive disorder will be enrolled in approximately 35 sites in North America. Participants will receive oral capsules of Icalcaprant or matching placebo once daily for 6 weeks, with a 30-day safety follow-up. There may be a higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Phase 2
Recruiting

Sunwise Clinical Research /ID# 277555 (+12 Sites)

ABBVIE INC.

AbbVie

Have you considered Aripiprazole clinical trials?

We made a collection of clinical trials featuring Aripiprazole, we think they might fit your search criteria.
Go to Trials